Author: Mark McCord
Run-on options for schemes small and large set to become real consideration for UK defined benefit pension sponsors.
Continued improvements in organ transplant techniques and procedures are increasing the success rate and post-operation life expectancy.
Pension Schemes Act will codify the operating rules and expectations of superfunds in the UK’s pensions industry.
Multiple reasons exist as to why biohacking is unlikely to impact mortality curves.
PRTs in the Netherlands have been steadily increasing since the government passed the Futures of Pensions Act.
New Prudential Regulation Authority consultation paper spells out the new capital charge for funded reinsurance deals.
Business may be brisk in the UK pension risk transfer market, but human capital constraints mean lower activity than is potentially possible.
Industry continues to model the potential upside of a successful rollout of MCED technology despite its newness.
Efforts to find treatments that slow or prevent Alzheimer’s disease are making good progress, but the complexities of tackling the illness are making it difficult to estimate what impact they will have on future mortality rates. A new report by reinsurer RGA on the current state of play in Alzheimer’s research stated that a combination of disease-modifying therapies and better understanding of the causes and progression of Alzheimer’s “point to a future that is cautiously but meaningfully brighter”. Nevertheless, its authors said that the likelihood of these developments substantially improving life expectancy was low because other more deadly diseases are still extant. “Most experts agree that disease-modifying treatments for…
WTW’s De-Risking Report 2026 suggests that longevity swaps are becoming increasingly interesting to UK defined benefit pension schemes and forecasts £20bn worth of transactions this year.